A method for determining whether a subject is at risk of dying from prostate cancer; wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at least one biomarker of the following in the biological sample: - glycoprotein acetyls, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids, - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-3 fatty acids to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - histidine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value(s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of dying from prostate cancer; wherein the at least one biomarker comprises or is glycoprotein acetyls, wherein an increase in the quantitative value of glycoprotein acetyls, when compared to the control sample or to the control value, is indicative of the subject having an increased risk of dying from prostate cancer; and wherein glycoprotein acetyls refers to a nuclear magnetic resonance spectroscopy signal that represents the abundance of circulating glycated proteins. wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at least one biomarker of the following in the biological sample: - glycoprotein acetyls, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids, - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-3 fatty acids to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - histidine; and - glycoprotein acetyls, - a ratio of docosahexaenoic acid to total fatty acids, - a ratio of linoleic acid to total fatty acids, - a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, - a ratio of omega-3 fatty acids to total fatty acids, - a ratio of omega-6 fatty acids to total fatty acids, - a ratio of saturated fatty acids to total fatty acids, - fatty acid degree of unsaturation, - histidine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value(s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of dying from prostate cancer; wherein the at least one biomarker comprises or is glycoprotein acetyls, wherein an increase in the quantitative value of glycoprotein acetyls, when compared to the control sample or to the control value, is indicative of the subject having an increased risk of dying from prostate cancer; and wherein glycoprotein acetyls refers to a nuclear magnetic resonance spectroscopy signal that represents the abundance of circulating glycated proteins.